• 1
    Stein H, Mason DY, Gerdes J, et al. The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood. 1985; 66: 848858.
  • 2
    Stansfeld AG, Diebold J, Noel H, et al. Updated Kiel classification for lymphomas. Lancet. 1988; 1: 292293.
  • 3
    Harris NL, Jaffe ES, Stein H, et al. Revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994; 84: 13611392.
  • 4
    Stein H, Foss HD, Durkop H, et al. CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood. 2000; 96: 36813695.
  • 5
    Falini B, Bigerna B, Fizzotti M, et al. ALK expression defines a distinct group of T/null lymphomas (“ALK lymphomas”) with a wide morphological spectrum. Am J Pathol. 1998; 153: 875886.
  • 6
    Falini B. Anaplastic large cell lymphoma: pathological, molecular and clinical features. Br J Haematol. 2001; 114: 741760.
  • 7
    Jaffe ES. Anaplastic large cell lymphoma: the shifting sands of diagnostic hematopathology. Mod Pathol. 2001; 14: 219228.
  • 8
    Rimokh R, Magaud JP, Berger F, et al. A translocation involving a specific breakpoint (q35) on chromosome 5 is a characteristic of anaplastic large cell lymphoma (ki-1 lymphoma). Br J Haematol. 1989; 71: 3136.
  • 9
    Downing JR, Shurtleff SA, Zielenska M, et al. Molecular detection of the (2;5) translocation of non-Hodgkin's lymphoma by reverse transcriptase-polymerase chain reaction. Blood. 1995; 85: 34163422.
  • 10
    Pulford K, Lamant L, Morris SW, et al. Detection of anaplastic lymphoma kinase (ALK) and nucleolar protein nucleophosmin (NPM) -ALK proteins in normal and neoplastic cells with the monoclonal antibody ALK1. Blood. 1997; 89: 13941404.
  • 11
    Liang X, Meech SJ, Odom LF, et al. Assessment of t(2;5)(p23;q35) translocation and variants in pediatric ALK+ anaplastic large cell lymphoma. Am J Clin Pathol. 2004; 121: 496506.
  • 12
    Delsol G, Al Saati T, Gatter KC, et al. Coexpression of epithelial membrane antigen (EMA), Ki-1, and interleukin-2 receptor by anaplastic large cell lymphomas. Diagnostic value in so-called malignant histiocytosis. Am J Pathol. 1988; 130: 5970.
  • 13
    Wright D, McKeever P, Carter R. Childhood non Hodgkin lymphomas in the United Kingdom: findings from the UK Children's Cancer Study Group. J Clin Pathol. 1997; 50: 128134.
  • 14
    Pizzo PA, Poplack DG. Principles and practice of pediatric oncology. 4th ed. Philadelphia: J.B. Lippincott, 2002.
  • 15
    Sandlund JT, Pui CH, Roberts WM, et al. Clinicopathologic features and treatment outcome of children with large-cell lymphoma and the t(2;5)(p23;q35). Blood. 1994; 84: 24672471.
  • 16
    Reiter A, Schrappe M, Tiemann M, et al. Successful treatment strategy for Ki-1 anaplastic large-cell lymphoma of childhood: a prospective analysis of 62 patients enrolled in three consecutive Berlin-Frankfurt-Münster group studies. J Clin Oncol. 1994; 12: 899908.
  • 17
    Brugières L, Le Deley MC, Pacquement H, et al. CD 30+ anaplastic large-cell lymphoma in children: analysis of 82 patients enrolled in two consecutive studies of the French Society of Pediatric Oncology. Blood. 1998; 92: 35913598.
  • 18
    Abdulkader I, Cameselle-Teijeiro J, Fraga M, Rodriguez-Nunez A, Allut AG, Forteza J. Primary anaplastic large cell lymphoma of the central nervous system. Hum Pathol. 1999; 30: 978981.
  • 19
    Vecchi V, Burnelli R, Pileri S, et al. Anaplastic large cell lymphoma (Ki-1+/CD30+) in childhood. Med Pediatr Oncol. 1993; 21: 402410.
  • 20
    Massimino M, Gasparini M, Giardini R. Ki-1 (CD30) anaplastic large-cell lymphoma in children. Ann Oncol. 1995; 6: 915920.
  • 21
    Mora J, Filippa DA, Thaler HT, et al. Large cell non-Hodgkin lymphoma of childhood: analysis of 78 consecutive patients enrolled in 2 consecutive protocols of the Memorial Sloan-Kettering Cancer Center. Cancer. 2000; 88: 186197.
  • 22
    Seidemann K, Tiemann M, Schrappe M, et al. Short-pulse B-non-Hodgkin lymphoma-type chemotherapy is efficacious treatment for pediatric anaplastic large cell lymphoma: a report of the Berlin-Frankfurt-Munster Group Trial NHL-BFM 90. Blood. 2001; 97: 36993706.
  • 23
    Williams DM, Hobson R, Imeson J, et al. Anaplastic large cell lymphoma in childhood: analysis of 72 patients treated on The United Kingdom Children's Cancer Study Group chemotherapy regimens. Br J Haematol. 2002; 117: 812820.
  • 24
    Wollner N. Non-Hodgkin's lymphoma in children; diffuse lymphoblastic histology; diffuse non-lymphoblastic histology; LSA2–L2 experience. An Esp Pediatr. 1988; 29(Suppl 34): 122126.
  • 25
    Murphy SB. Classification, staging and results of treatment of childhood non-Hodgkin's lymphoma: dissimilarities from lymphomas in adults. Semin Oncol. 1980; 7: 332339.
  • 26
    Lopez-Andrew JA, Ferris J, Verdeguer A, Esquembre C, Senent ML, Castel V. Secondary acute promyelocytic leukemia in a child treated with epipodophyllotoxins. Am J Pediatr Hematol Oncol. 1994; 16: 384386.
  • 27
    Kaplan EL, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc. 1958; 53: 457481.
  • 28
    Peto R, Peto J. Asymptotically efficient rank invariant test procedures. J R Stat Soc A. 1972; 135: 185198.
  • 29
    Laver JH, Kraveka JM, Hutchison RE, et al. Advanced-stage large-cell lymphoma in children and adolescents: results of a randomized trial incorporating intermediate-dose methotrexate and high-dose cytarabine in the maintenance phase of the APO regimen: a Pediatric Oncology Group phase III trial. J Clin Oncol. 2005; 23: 541547.
  • 30
    Brugieres L, Le-Deley MC, Pacquement H, et al. Relapses of of childhood anaplastic large-cell lymphoma: treatment results in a series of 41 children-a report from the French Society of Pediatric Oncology. Ann Oncol. 2000; 11: 5358.